Metastatic non-small cell lung cancer management: Novel targets and recent clinical advances

Jonathan Riess, Heather A. Wakelee

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Lung cancer continues to be the most common cause of cancer-related mortality in the United States and other developed countries. The most common subtype is non-small cell lung cancer (NSCLC). Within NSCLC, we are discovering remarkable molecular heterogeneity. Most current actionable mutations have been identified in patients with adenocarcinoma histology, but now new mutations are being discovered in squamous cell histology patients as well. This molecular heterogeneity provides an opportunity for clinical trials to exploit various candidate oncogene-addicted pathways in NSCLC. This article focuses on 2 shifting paradigms in NSCLC management: the recent advances in targeted therapy and maintenance treatment.

Original languageEnglish (US)
Pages (from-to)226-234
Number of pages9
JournalClinical Advances in Hematology and Oncology
Volume10
Issue number4
StatePublished - Apr 2012
Externally publishedYes

Keywords

  • Chemotherapy
  • Clinical trials
  • Molecular markers
  • Non-small cell lung cancer
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Hematology

Fingerprint Dive into the research topics of 'Metastatic non-small cell lung cancer management: Novel targets and recent clinical advances'. Together they form a unique fingerprint.

  • Cite this